FDA Update News From the Journals

Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial

October 21, 2024 By The ASCO Post Staff 1 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

On October 18, Gilead Sciences announced its plans to voluntarily withdraw the U.S. accelerated approval for sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and PD-1 or PD-L1 inhibitor. This decision was made in consultation with the U.S. Food and Drug Administration (FDA) and does not affect the other approved indications for the treatment.

Sacituzumab govitecan, a TROP-2–directed antibody-drug conjugate, was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response data from cohort 1 of the global phase II, single-arm TROPHY-U-01 study. Continued approval for this indication was contingent on verification and description of clinical benefit in the confirmatory TROPiCS-04 study. Earlier this year, Gilead announced that the TROPiCS-04 study did not meet the primary endpoint of overall survival in the intention-to-treat population. These data will be presented at an upcoming medical meeting.

Health-care providers will be notified of this update. Patients receiving sacituzumab govitecan for metastatic urothelial cancer in the United States should discuss their care with their health-care provider.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.